SURMOUNT-5 is the only published head-to-head trial comparing semaglutide and tirzepatide at their maximum approved weight management doses. The result was decisive. Jastreboff et al. published the data in the New England Journal of Medicine in 2025: 751 adults with obesity and without diabetes, randomized to tirzepatide (Zepbound) 15mg or semaglutide (Wegovy) 2.4mg weekly for 72 weeks, open-label.
Tirzepatide produced 20.2% mean weight loss. Semaglutide produced 13.7%. That is a 47% greater relative weight reduction with tirzepatide, and it met the primary endpoint with statistical superiority on all five key secondary endpoints.
This was not a close result.
The percentage difference becomes more concrete at scale. For a 250-pound individual, semaglutide's 13.7% translates to roughly 34 pounds lost. Tirzepatide's 20.2% translates to roughly 50 pounds. That is a 16-pound difference at the same treatment duration.
The response distribution matters as much as the mean. In SURMOUNT-1, 56% of participants on tirzepatide 15mg achieved 20% or more body weight reduction. In STEP-1, 32% of semaglutide participants achieved 15% or more. These are different thresholds from different trials, but they reflect a consistent pattern: tirzepatide pushes a larger proportion of patients into the range of weight loss previously associated only with bariatric surgery.
The difference is not simply "more of the same." Semaglutide is a selective GLP-1 receptor agonist. Tirzepatide is a dual GIP/GLP-1 receptor agonist engineered from the native GIP sequence with GLP-1 activity added. It binds the GIP receptor with affinity equal to native GIP while binding GLP-1 receptors with approximately 5-fold weaker affinity than native GLP-1.
This creates a pharmacological paradox: tirzepatide is actually a weaker GLP-1 agonist than semaglutide, yet it produces substantially more weight loss. The additional weight loss comes from the GIP receptor component, which activates partially distinct appetite-suppressing circuits in the hypothalamus and has direct effects on adipose tissue lipid metabolism. The precise mechanism of GIP's contribution to weight loss is still being characterized, but the clinical result is not in dispute.
The weight loss comparison favors tirzepatide, but the evidence base is not symmetrical across all outcomes.
Semaglutide has the SELECT trial. This is a cardiovascular outcomes trial of 17,604 non-diabetic participants with obesity and established cardiovascular disease, followed for a mean of 39.8 months. It demonstrated a 20% reduction in major adverse cardiovascular events (MACE: cardiovascular death, nonfatal MI, nonfatal stroke) with a hazard ratio of 0.80 (P<0.001). No other GLP-1 or GIP/GLP-1 agonist has demonstrated MACE reduction in a non-diabetic obesity population.
Tirzepatide's SURPASS-CVOT (n=13,299, published NEJM December 2025) showed noninferiority to dulaglutide for MACE in type 2 diabetes, but this is a different population, a different comparator, and a different question than SELECT answered. SURMOUNT-MMO (tirzepatide's dedicated obesity morbidity/mortality trial) is ongoing but has not reported.
Semaglutide also has the FLOW trial (n=3,534) demonstrating a 24% reduction in major kidney disease events, and the ESSENCE trial demonstrating 62.9% MASH resolution at 72 weeks. Tirzepatide has strong renal and hepatic signals from secondary analyses but no dedicated outcomes trials in these domains with published results. Read the full semaglutide profile and tirzepatide profile for complete evidence tables.
Semaglutide has an oral formulation. Oral Wegovy 25mg was approved in December 2025 and demonstrated 16.6% weight loss at 64 weeks in OASIS-4. Tirzepatide is injection-only.
Both drugs share the same critical limitation: stopping treatment reverses the benefit. STEP-1 extension data showed approximately 75% of semaglutide-associated weight loss regained within 12 months of discontinuation. SURMOUNT-1 3-year data showed the same pattern for tirzepatide. This is not a failure of the drugs. It is the nature of chronic disease treatment. Stopping either medication is mechanistically equivalent to stopping an antihypertensive and expecting blood pressure to stay low.
The practical implication: the choice between semaglutide and tirzepatide is a choice about long-term, potentially lifelong therapy. The 6.5 percentage point weight loss difference at 72 weeks compounds into a meaningful quality-of-life difference over years of continuous use.
Both drugs share GLP-1 class adverse effects: nausea, vomiting, diarrhea, and constipation during dose escalation are the primary tolerability concerns. Both carry the same boxed warning for thyroid C-cell tumors observed in rodent studies (human relevance unknown). Both are contraindicated with personal or family history of medullary thyroid carcinoma.
STEP-1 reported nausea in 44% of semaglutide patients versus 16% placebo. SURMOUNT-1 reported nausea in 25 to 45% of tirzepatide patients depending on dose. GI-related discontinuation rates are broadly comparable: 10% in SELECT (semaglutide) versus 13.3% in SURPASS-CVOT (tirzepatide), though these are different trial populations and durations.
Both drugs are prohibited by WADA. Neither is available through legal compounding in the United States as of April 2026 (tirzepatide shortage ended October 2024; semaglutide compounding faces ongoing enforcement).
The semaglutide vs tirzepatide comparison may soon be superseded. Retatrutide (Eli Lilly) is a triple GIP/GLP-1/glucagon receptor agonist that produced 24.2% weight loss at 48 weeks in Phase 2 and 28.7% at 68 weeks in the Phase 3 TRIUMPH-4 trial (n=445, December 2025). All primary and key secondary endpoints were met. Seven additional Phase 3 readouts are expected in 2026.
The addition of glucagon receptor agonism to the GIP/GLP-1 platform increases energy expenditure through thermogenesis and reduces hepatic fat through mechanisms distinct from incretin activity. If the remaining TRIUMPH data confirms the Phase 2 signal, retatrutide will establish a new benchmark above tirzepatide.
SURMOUNT-5 provides a clear, head-to-head answer: tirzepatide produces approximately 47% greater weight loss than semaglutide at maximum approved doses. The result is statistically and clinically significant.
Semaglutide retains meaningful advantages in cardiovascular outcomes data (SELECT is unmatched), renal outcomes (FLOW), MASH treatment (ESSENCE), and oral availability. For a patient whose primary goal is maximum weight reduction, tirzepatide is the superior agent. For a patient with established cardiovascular disease, semaglutide has the stronger evidence base for hard outcomes reduction. Both require chronic use. Both share the same class safety profile. Both are prohibited in sport.
The honest assessment: this is not a case where one drug is universally better. It is a case where two drugs with different evidence portfolios serve different clinical priorities, and the weight loss hierarchy is unambiguous.
For research and educational purposes only · Not medical advice · Consult a qualified physician before any human use